A special budget for Alzheimer’s and related dem
Post# of 30028
Posted On: 08/05/2015 8:02:21 PM
A special budget for Alzheimer’s and related dementias
Posted on August 5, 2015
We estimate that an additional $323 million would be needed, above an assumed baseline appropriation for fiscal year 2017, as an increased investment for meeting the national research goal.
Where would the money go?
These funds would be applied across the research spectrum, from basic science to translational to clinical research. Examples include but are not limited to:
Discovery and validation of novel targets for therapy development based on gene, protein, and metabolic networks;
Integrating studies of the fundamental biology/neurobiology of aging with Alzheimer’s research;
Adding molecular phenotyping and genotyping to longitudinal cohort studies, especially in those individuals at highest risk of disease;
Phase I, II, and III drug and nonpharmacological clinical trials in presymptomatic, cognitively impaired, and symptomatic individuals, including those with neuropsychiatric symptoms;
Development of novel imaging and biofluid biomarkers for early diagnosis and clinical trial outcomes;
Research to design and test clinical interventions and models of care for people with dementia and their caregivers.
https://www.nia.nih.gov/research/blog/2015/08...-dementias
Posted on August 5, 2015
We estimate that an additional $323 million would be needed, above an assumed baseline appropriation for fiscal year 2017, as an increased investment for meeting the national research goal.
Where would the money go?
These funds would be applied across the research spectrum, from basic science to translational to clinical research. Examples include but are not limited to:
Discovery and validation of novel targets for therapy development based on gene, protein, and metabolic networks;
Integrating studies of the fundamental biology/neurobiology of aging with Alzheimer’s research;
Adding molecular phenotyping and genotyping to longitudinal cohort studies, especially in those individuals at highest risk of disease;
Phase I, II, and III drug and nonpharmacological clinical trials in presymptomatic, cognitively impaired, and symptomatic individuals, including those with neuropsychiatric symptoms;
Development of novel imaging and biofluid biomarkers for early diagnosis and clinical trial outcomes;
Research to design and test clinical interventions and models of care for people with dementia and their caregivers.
https://www.nia.nih.gov/research/blog/2015/08...-dementias
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼